Nanthealth Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nanthealth Inc (NHIQ) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Nanthealth Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 63M vs 2,097M combined for tracked competitors (2.9% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-23.1% annualized vs trailing 12 months), vs decelerating (-2.5%) for its tracked peer group.
- Growth: Nanthealth Inc generated -23.2% revenue growth year over year in Q3 2023, vs 44.9% for its tracked competitors combined.
- Profitability: Its -124.3% net margin compares with -5.0% for the peer group.
- Peer revenue share: Nanthealth Inc accounted for 2.3% of combined revenue among its tracked peer group, down from 4.3% a year earlier.
- Peer differentiation: Revenue per employee of $0.31M compares with $0.50M for the peer group (0.6x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NHIQ Sales vs. its Competitors, Q3 2023
Nanthealth Inc reported revenue contraction of 23.22 % year on year in Q3 2023, below its competitors' combined revenue growth of 44.93 %.
With a net margin of -124.29 %, Nanthealth Inc reported lower profitability than its competitors (-4.96 %).
Nanthealth Inc generated 2.31 % of the combined sales of its peer group, down from 4.26 % a year earlier.
Nanthealth Inc vs. its Competitors, Q3 2023
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Nanthealth Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Nanthealth Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Nanthealth Inc's competitor groups requires a Commercial License.
For context: the Cloud Computing & Data Analytics industry grew revenue 1.3% year over year, combined, vs -23.2% for Nanthealth Inc. Nanthealth Inc's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Nanthealth Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nanthealth Inc | No | No | No | No |
| Competitors combined (1) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) | 37.50 % (3 of 8) | 14.30 % (1 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NHIQ Stock Performance relative to its Competitors
NHIQ Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Evolent Health Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nanthealth Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Nanthealth Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Nanthealth Inc | 0.03 | 62.73 |
| Evolent Health Inc | 409.09 | 2,097.02 |
| SUBTOTAL | 409.12 | 2,159.75 |
Sources: Nanthealth Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nanthealth Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nanthealth Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Evolent Health Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Nanthealth Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nanthealth Inc | 0 | 307,500 | -344,966 |
| Evolent Health Inc | 409 | 499,290 | -120,236 |
| PEERS TOTAL | 409 | 499,290 | -120,236 |
Nanthealth Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Cloud Computing & Data Analytics industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (203 companies). See the full Cloud Computing & Data Analytics industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 62.72 % | 51.85 % (avg) | +10.9 pp |
| Operating Margin | -70.84 % | industry median | -67.9 pp |
| EBITDA Margin | -78.87 % | 2.97 % (avg) | -81.8 pp |
| Capital Intensity (Capex / Revenue) | - | 5.21 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Nanthealth Inc's Valuation vs Competitive Position
Valuation multiples vs the Cloud Computing & Data Analytics industry average (203 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Cloud Computing & Data Analytics industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 27.6x | - |
| EV / EBITDA | - | 16.4x | - |
| P/B | 0.0x | 4.0x | -4.0x |
| Return on Equity | 29.16 % | industry aggregate | 24.44 % |
| Return on Invested Capital | 33.71 % | 1.95 % (avg) | 31.76 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Nanthealth Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue Growth | 3.22 % | 7.26 % | -23.75 % | -14.38 % | 4.63 % |
| Operating Margin | -56.67 % | -32.07 % | -35.90 % | -65.28 % | -78.30 % |
| Return on Invested Capital | -12.05 % | -16.12 % | -27.28 % | -72.67 % | -1,374.12 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nanthealth Inc's Strategic Group Map
Every company in Nanthealth Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Nanthealth Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Nanthealth Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Nanthealth Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Nanthealth Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Return on equity 24.4 points above the industry aggregate.
Weaknesses
- Operating margin 67.9 points below the industry median.
- Latest-quarter revenue run-rate is decelerating (-23.1% annualized vs trailing 12 months).
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-2.5% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Nanthealth Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nanthealth Inc | 0.09 | 0.21 | - |
| Evolent Health Inc | 0.37 | 1.30 | 1.95 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nanthealth Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nanthealth Inc | Q3 2023 | -23.2 % | - |
| Evolent Health Inc | Q2 2026 | +46.9 % | - |
| PEERS TOTAL | +44.5 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nanthealth Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nanthealth Inc | Q3 2023 | -16.7 % | - |
| Evolent Health Inc | Q2 2026 | +66.2 % | -21.9 % |
Nanthealth Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nanthealth Inc | - | - | - |
| Evolent Health Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nanthealth Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nanthealth Inc | - | 0.00 |
| Evolent Health Inc | - | 0.20 |
| PEERS AVERAGE | - | 0.19 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.